GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD
This study will determine the effectiveness of MK0777 GEM versus Lorazepam in the treatment of patients with generalized anxiety disorder.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Please refer to this study by its ClinicalTrials.gov identifier: NCT00546624
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|